In a mouse model of hepatocellular carcinoma, transformation with kinase-inactivated integrin-linked kinase (KI-ILK) partially restored the sensitivity to anti-EGFR treatment [141]. This evidence concerns the gene ILK and hepatocellular carcinoma.